You are here
Products
ROS [MD15R]
Product group: | Primary |
Monoclonal/ Polyclonal: | Monoclonal |
Clone: | MD15R |
Host: | Rabbit |
Isotype: | IgG |
Application: | Immunocytochemistry (ICC),Immunofluorescence (IF), Immunohistochemistry on paraffin sections (IHC-P), Immunoprecipitation (IP), Western Blot (WB) |
Application notes: | Prediluted |
Conjugation Type: | Unconjugated |
Reactivity: | Human |
General notes: | Localization: membrane. |
Buffer: | EDTA pH8.0 |
UNSPSC code: | 12352203 |
ROS or ROS1, a 263914 Da cell membrane tyrosine kinase expressed in brain, an orphan receptor tyrosine kinase of the insulin receptor family, was initially identified as a homolog of v-ros from the UR2 sarcoma virus. ROS consists of a large extracellular domain that is composed of six fibronectin repeats, a transmembrane domain, and an intracellular kinase domain. While the function of ROS is undefined, it has been shown to play an important role in differentiation of epididymal epithe. The first oncogenic fusion of ROS, FIG-ROS1, was initially identified by research studies in glioblast, and subsequent studies have found this fusion in cholangiocarcinoa, ovarian can and non-small cell lung cancer (NSCLC). Investigators have found additional oncogenic ROS fusion proteins in NSCLC (at a frequency of ~1.6%), where the ROS1 kinase domain is fused to the amino-terminal region of a number of different proteins, including CD74 and SLC34A. ROS fusion proteins activate the SHP-2 phosphatase, P
ROS [MD15R]
ROS or ROS1, a 263914 Da cell membrane tyrosine kinase expressed in brain, an orphan receptor tyrosine kinase of the insulin receptor family, was initially identified as a homolog of v-ros from the UR2 sarcoma virus. ROS consists of a large extracellular domain that is composed of six fibronectin repeats, a transmembrane domain, and an intracellular kinase domain. While the function of ROS is undefined, it has been shown to play an important role in differentiation of epididymal epithe. The first oncogenic fusion of ROS, FIG-ROS1, was initially identified by research studies in glioblast, and subsequent studies have found this fusion in cholangiocarcinoa, ovarian can and non-small cell lung cancer (NSCLC). Investigators have found additional oncogenic ROS fusion proteins in NSCLC (at a frequency of ~1.6%), where the ROS1 kinase domain is fused to the amino-terminal region of a number of different proteins, including CD74 and SLC34A. ROS fusion proteins activate the SHP-2 phosphatase, PI3K/Akt/mTOR, Erk, and Stat3 pathwa. This antibody recognizes endogenous levels of total ROS protein. It does not cross-react with other related proteins when analyzed by western blot. Please note that staining may be observed in ROS rearranged lung carcinomas, macrophages/giant cells, reactive type II pneumocyte hyperplasia, and the epithelium in areas of bronchiolar metaplasia. Staining of unknown specificity has been observed in cholangiocarcinoma, hepatocellular carcinoma, and kidney tissues.
Alternative names: